Group		Control			bumetrizole		
mg/kg		0		62.5	250	1000	
lumber of females		12		12	12	12	
Observation of animals of	n observer's palm						
Lacrimation	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
Salivation	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
Respiration	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]

Figures in parentheses [] indicate number of females.

Findings were graded as follows

Lacrimation

1: None, 2: mild, 3: marked.

Salivation

1: None, 2: mild, 3: marked.

Respiration

1: Normal, 2: bradypnea, 3: dyspnea.

- 76 -506

Table 17-5 FOB of female rats in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group		Control			bumetrizole	
mg/kg		0		62.5	250	1000
Number of females		12		12	12	12
Open-field test						
Frequency of rearing	Pre	9.3 ± 4.8		8.8 ± 4.3	8.4 ± 5.2	9.8 ± 5.4
Mean ± S.D.	Day 8	7.5 ± 3.8		8.5 ± 2.9	6.2 ± 4.7	8.9 ± 5.7
	Day 15	5.7 ± 4.9		7.4 ± 4.6	6.0 ± 3.2	9.0 ± 7.4
	Day 1 of pregnancy	3.7 ± 2.6	[11]	6.3 ± 3.8	4.4 ± 3.9	5.2 ± 3.8 [11]
	Day 8 of pregnancy	7.8 ± 4.8	[11]	6.1 ± 3.6	7.1 ± 3.2	6.7 ± 4.7 [11]
	Day 15 of pregnancy	6.3 ± 5.8	[11]	6.4 ± 3.8	6.4 ± 4.9	8.5 ± 5.4 [11]
	Day 3 of lactation	5.9 ± 4.6	[11]	5.7 ± 2.7	5.2 ± 3.7	5.2 ± 3.9 [11]
Frequency of grooming	Pre	0.0 ± 0.0		0.0 ± 0.0	0.2 ± 0.6	0.1 ± 0.3
Mean \pm S.D.	Day 8	0.0 ± 0.0		0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
	Day 15	0.0 ± 0.0		0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
	Day 1 of pregnancy	0.0 ± 0.0	[11]	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0 [11]
	Day 8 of pregnancy	0.0 ± 0.0	[11]	0.0 ± 0.0	0.0 ± 0.0	0.3 ± 0.6 [11]
	Day 15 of pregnancy	0.0 ± 0.0	[11]	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0 [11]
	Day 3 of lactation	0.5 ± 0.9	[11]	0.3 ± 0.7	0.5 ± 0.9	0.1 ± 0.3 [11]
Gait	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
Palpebral closure	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1) [11]

Figures in parentheses [] indicate number of females.

Frequency of rearing (during a 2-minute period).

Frequency of grooming (during a 2-minute period).

Findings were graded as follows

Gait 1: Normal, 2: unmoving, 3: staggering, 4: hind-limbs extended and dragged, 5: all fours extended,

6: forelimbs extended and dragged; unable to support body, 7: standing on tiptoe.

Palpebral closure 1: Eyelids open normally, 2: eyelids half-closed, 3: eyelids closed.

Table 17-6 FOB of female rats in combined repeat dose and reproductive/developmental toxicity screening test of burnetrizole by oral administration

Group mg/kg		Control			bumetrizole		
		0		62.5	250	1000	
lumber of females		12		12	12	12	
pen-field test							
Consciousness	Pre	2.0 (2)	1	2.0 (2)	2.0 (2)	2.0 (2)	
Mean (range)	Day 8	2.0 (2)		2.0 (2)	2.0 (2)	2.0 (2)	
	Day 15	2.0 (2)		2.0 (2)	2.0 (2)	2.0 (2)	
	Day 1 of pregnancy	2.0 (2)	[11]	2.0 (2)	2.0 (2)	2.0 (2)	[11]
	Day 8 of pregnancy	2.0 (2)	[11]	2.0 (2)	2.0 (2)	2.0 (2)	[11]
	Day 15 of pregnancy	2.0 (2)	[11]	2.0 (2)	2.0 (2)	2.0 (2)	[11]
	Day 3 of lactation	2.0 (2)	[11]	2.0 (2)	2.0 (2)	2.0 (2)	[11]
Behavioral abnormalities	Pre	1.0 (1)	j	1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)	İ	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 3 of lactation	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
Righting reflex	Pre	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
` 5,	Day 15	1.0 (1)		1.0 (1)	1.0 (1)	1.0 (1)	
	Day 1 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 8 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 15 of pregnancy	1.0 (1)	[11]	1.0 (1)	1.0 (1)	1.0 (1)	[11]
	Day 3 of lactation	1.0 (1)	lini	1.0 (1)	1.0 (1)	1.0 (1)	[11]

Figures in parentheses [] indicate number of females.

Findings were graded as follows

Consciousness 1: Comatose; no response, 2: exploring behavior, 3: excited and moving spasmodically.

Behavioral abnormalities 1: Not observed, 2: straub's reaction, 3: moving backward, 4: writhing.

Righting reflex 1: Righting itself immediately, 2: requiring 3 seconds or longer to right itself, 3: unable to right itself.

Group		Control	bume	trizole
mg/kg		0	250	1000
Number of females		6	6	6
Observation of animals in cag	es			
Posture	Pre	2.0 (2)	2.0 (2)	2.0 (2)
Mean (range)	Day 8	2.0 (2)	2.0 (2)	2.0 (2)
	Day 15	2.0 (2)	2.0 (2)	2.0 (2)
	Day 22	2.0 (2)	2.0 (2)	2.0 (2)
	Day 29	2.0 (2)	2.0 (2)	2.0 (2)
	Day 36	2.0 (2)	2.0 (2)	2.0 (2)
	Day 42	2.0 (2)	2.0 (2)	2.0 (2)
Palpebral closure	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)
Biting behavior	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)
Clonic convulsions	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)

Posture

1: Prone or recumbent position, 2: resting normally, 3: moving or running about, 4: jumping.

Palpebral closure

1: Eyelids open normally, 2: eyelids half-closed, 3: eyelids closed.

Biting behavior

1: Not observed, 2: observed.

Clonic convulsions

1: Not observed, 2: jaw convulsions, 3: tremor.

- 79 -509

Table 18-2 FOB of female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of burnetrizole by oral administration

Group		Control	bumetrizole		
mg/kg		0	250	1000	
Number of females		6	6	6	
Observation of animals in cag	ges				
Tonic convulsions	Pre	1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)	

Tonic convulsions

1: Not observed, 2: tonic extension, 3: opisthotonus convulsions, 4: saltatory convulsions, 5: asphyxial convulsions.

Table 18-3 FOB of female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Group		bumet	rizole
mg/kg		0	250	1000
Number of females		6	6	6
Observation of animals on obser	ver's palm			
Ease of removal from ca	age Pre	2.0 (2)	2.0 (2)	2.0 (2)
Mean (range)	Day 8	2.0 (2)	2.0 (2)	2.0 (2)
	Day 15	2.0 (2)	2.0 (2)	2.0 (2)
	Day 22	2.0 (2)	2.0 (2)	2.0 (2)
	Day 29	2.0 (2)	2.0 (2)	2.0 (2)
	Day 36	2.0 (2)	2.0 (2)	2.0 (2)
	Day 42	2.0 (2)	2.0 (2)	2.0 (2)
Ease of handling	Pre	2.0 (2)	2.0 (2)	2.0 (2)
Mean (range)	Day 8	2.0 (2)	2.0 (2)	2.0 (2)
	Day 15	2.0 (2)	2.0 (2)	2.0 (2)
	Day 22	2.0 (2)	2.0 (2)	2.0 (2)
	Day 29	2.0 (2)	2.0 (2)	2.0 (2)
	Day 36	2.0 (2)	2.0 (2)	2.0 (2)
	Day 42	2.0 (2)	2.0 (2)	2.0 (2)
Muscle tone	Pre	2.0 (2)	2.0 (2)	2.0 (2)
Mean (range)	Day 8	2.0 (2)	2.0 (2)	2.0 (2)
	Day 15	2.0 (2)	2.0 (2)	2.0 (2)
	Day 22	2.0 (2)	2.0 (2)	2.0 (2)
	Day 29	2.0 (2)	2.0 (2)	2.0 (2)
	Day 36	2.0 (2)	2.0 (2)	2.0 (2)
	Day 42	2.0 (2)	2.0 (2)	2.0 (2)
Fur conditions	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
· - ,	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)

Ease of removal from cage

1: Docile and allowing itself to be handled, 2: rearing or cowering, 3: running about; hard to catch.

Ease of handling

1: Docile and allowing itself to be handled, 2: struggling slightly or vocalizing, 3: struggling and trying to bite observer's hand.

Muscle tone

1: Decreased, 2: normal, 3: increased.

Fur conditions

1: Normal, 2: slightly soiled, 3: markedly soiled.

511

Table 18-4 FOB of female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group		Control	bumetr	izole	
ng/kg		0	250	1000	
Number of females		6	6	6	
Observation of animals on o	bserver's palm				
Lacrimation	Pre	1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)	
Salivation	Pre	1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)	
-	Day 15	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)	
Respiration	Pre	1.0 (1)	1.0 (1)	1.0 (1)	
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)	
. • ,	Day 15	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)	
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)	

Lacrimation

1: None, 2: mild, 3: marked. 1: None, 2: mild, 3: marked.

Respiration

Salivation

1: Normal, 2: bradypnea, 3: dyspnea.

Table 18-5 FOB of female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group		Control	bume	trizole
mg/kg		0	250	1000
Number of females		6	6	6
Open-field test				
Frequency of rearing	Pre	5.5 ± 2.9	10.7 ± 2.9 *	6.2 ± 3.3
$Mean \pm S.D.$	Day 8	4.8 ± 5.3	6.0 ± 3.7	3.3 ± 2.3
	Day 15	6.0 ± 4.6	8.8 ± 5.7	6.0 ± 3.9
	Day 22	5.0 ± 4.3	7.0 ± 4.6	5.7 ± 2.9
	Day 29	4.5 ± 3.3	8.8 ± 4.5	7.5 ± 3.8
	Day 36	3.5 ± 1.9	11.2 ± 4.4 **	7.7 ± 3.1
	Day 42	9.0 ± 2.0	11.5 ± 4.1	8.5 ± 5.2
Frequency of grooming	Pre	0.0 ± 0.0	0.0 ± 0.0	0.2 ± 0.4
$Mean \pm S.D.$	Day 8	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
	Day 15	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
	Day 22	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
	Day 29	0.0 ± 0.0	0.2 ± 0.4	0.0 ± 0.0
	Day 36	0.0 ± 0.0	0.3 ± 0.8	0.3 ± 0.8
	Day 42	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
Gait	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)
Palpebral closure	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
, ,,	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)

Significantly different from control group (*: P<0.05, **: P<0.01).

Gait

Palpebral closure

1: Eyelids open normally, 2: eyelids half-closed, 3: eyelids closed.

Frequency of rearing (during a 2-minute period).

Frequency of grooming (during a 2-minute period).

Findings were graded as follows

^{1:} Normal, 2: unmoving, 3: staggering, 4: hind-limbs extended and dragged, 5: all fours extended,

^{6:} forelimbs extended and dragged; unable to support body, 7: standing on tiptoe.

Table 18-6 FOB of female rats (recovery group) in combined repeat dose and reproductive/developmental toxicity screening test of burnetrizole by oral administration

Group		Control	bu	metrizole
mg/kg		0	250	1000
Number of females		6	6	6
Open-field test				
Consciousness	Pre	2.0 (2)	2.0 (2)	2.0 (2)
Mean (range)	Day 8	2.0 (2)	2.0 (2)	2.0 (2)
	Day 15	2.0 (2)	2.0 (2)	2.0 (2)
	Day 22	2.0 (2)	2.0 (2)	2.0 (2)
	Day 29	2.0 (2)	2.0 (2)	2.0 (2)
	Day 36	2.0 (2)	2.0 (2)	2.0 (2)
	Day 42	2.0 (2)	2.0 (2)	2.0 (2)
Behavioral abnormalities	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)
Righting reflex	Pre	1.0 (1)	1.0 (1)	1.0 (1)
Mean (range)	Day 8	1.0 (1)	1.0 (1)	1.0 (1)
, ,,	Day 15	1.0 (1)	1.0 (1)	1.0 (1)
	Day 22	1.0 (1)	1.0 (1)	1.0 (1)
	Day 29	1.0 (1)	1.0 (1)	1.0 (1)
	Day 36	1.0 (1)	1.0 (1)	1.0 (1)
	Day 42	1.0 (1)	1.0 (1)	1.0 (1)

Consciousness

1: Comatose; no response, 2: exploring behavior, 3: excited and moving spasmodically.

Behavioral abnormalities

1: Not observed, 2: straub's reaction, 3: moving backward, 4: writhing.

Righting reflex

1: Righting itself immediately, 2: requiring 3 seconds or longer to right itself, 3: unable to right itself.

Table 19 Sensory response of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole				
mg/kg	0	62.5	250	1000		
Number of males	6	6	6	6		
Pupillary reflex						
Mean (range)	1.0 (1)	1.0 (1)	1.0 (1)	1.0 (1)		
Approaching behavior		, ,	` ,	` '		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Response to touch		` '	` ,	` ,		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Auditory reflex		, ,	, í	` ,		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Pain reflex		` ,	`	` ,		
Mean (range)	3.0 (3)	3.0 (3)	3.0 (3)	3.0 (3)		

Pupillary reflex

Approaching behavior

Response to touch

Auditory reflex Pain reflex 1: Normal pupillary contraction observed, 2: pupils completely dilated, 3: pupils completely contracted.

1: Not observed, 2: approaching and sniffing stimulus, 3: reacting to stimulus, including vocalizing,

4: jumping at or biting at stimulus.

1: No response, 2: looking back and leaving stimulus, 3: reacting to stimulus, including vocalizing,

4: jumping at or biting at stimulus.

1: Not observed, 2: hesitating at stimulus or moving ears, 3: jumping at and trying to bite at the source of sound.

1: Not observed, 2: slowly looking back or slowly moving forward to escape from stimulus,

3: quickly moving forward to escape from stimulus or biting at it immediately after looking back,

4: jumping forward to escape from stimulus, 5: loudly vocalizing and biting at stimulus after suddenly looking back.

Table 20 Sensory response of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole				
mg/kg	0	62.5	250	1000		
Number of females	6	6	6	6		
Pupillary reflex						
Mean (range)	1.0 (1)	1.0 (1)	1.0 (1)	1.0 (1)		
Approaching behavior		` ,	` '	, ,		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Response to touch		. ,	, ,	. ,		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Auditory reflex		. ,		. ,		
Mean (range)	2.0 (2)	2.0 (2)	2.0 (2)	2.0 (2)		
Pain reflex		` ,	` '	` ,		
Mean (range)	3.0 (3)	3.0 (3)	3.0 (3)	3.0 (3)		

Pupillary reflex

Approaching behavior

Response to touch

.

Auditory reflex Pain reflex 1: Normal pupillary contraction observed, 2: pupils completely dilated, 3: pupils completely contracted.

1: Not observed, 2: approaching and sniffing stimulus, 3: reacting to stimulus, including vocalizing,

4: jumping at or biting at stimulus.

1: No response, 2: looking back and leaving stimulus, 3: reacting to stimulus, including vocalizing,

4: jumping at or biting at stimulus.

1: Not observed, 2: hesitating at stimulus or moving ears, 3: jumping at and trying to bite at the source of sound.

1: Not observed, 2: slowly looking back or slowly moving forward to escape from stimulus,

3: quickly moving forward to escape from stimulus or biting at it immediately after looking back,

4: jumping forward to escape from stimulus, 5: loudly vocalizing and biting at stimulus after suddenly looking back.

Table 21 Grip strength of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control		bumetrizole	
mg/kg	0	62.5	250	1000
Number of males	6	6	6	6
Forelimb Hindlimb	1029 ± 325	1122 ± 255	1120 ± 301	954 ± 252
	118 ± 44	148 ± 103	137 ± 58	117 ± 40

Each value shows mean $(g) \pm S.D.$

Table 22 Grip strength of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole		
mg/kg	0	62.5	250	1000
Number of females	6	6	6	6
Forelimb				
	959 ± 185	791 ± 90	799 ± 145	860 ± 240
Hindlimb	1			
	121 ± 48	93 ± 41	74 ± 18	118 ± 58

Each value shows mean $(g) \pm S.D.$

Table 23 Spontaneous motor activity of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Con	trol	bumetrizole						
mg/kg	0	0 62.5 250 1000)					
Number of males	6			6		6		6	
Ambulatory counts									
Minutes after administration									
10	1188 ±	561	1044 ±	517	878	± 436	678	±	325
20	395 ±	386	1168 ±	2109	328	± 261	871	±	1568
30	127 ±	120	467 ±	792	260	± 239	238	±	292
40	181 ±	240	188 ±	166	191	± 233	156	±	288
50	59 ±	95	151 ±	182	108	± 108	190		327
60	204 ±	239	169 ±	273	2	± 4 *	152		273
Total	2153 ±	825	3187 ±	3493	1765	± 1020	2285		3007
Vertical counts									
Minutes after administration									
10	62 ±	20	59 ±	28	58	± 12	40	±	18
20	22 ±	14	23 ±	17	28	± 18	15		10
30	7 ±	9	17 ±	23	15	± 12		±	8
40	10 ±	13	10 ±	14	12	± 16	2	±	2
50	6 ±	12	4 ±			± 7	_	±	6
60	11 ±	13	5 ±	7	0	± 0 *	2	±	3
Total	118 ±	64	118 ±	77	119		66		33

Each value shows mean \pm S.D.

Significantly different from control group (*: P<0.05).

Table 24 Spontaneous motor activity of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	(Control		bumetrizole								
mg/kg		0		62.5			250			1000		
Number of females		6			6				6			6
Ambulatory counts												
Minutes after administration												
10	1015	± 496	922	2 ±	: 30	1	891	=	± 450	1222	±	1334
20	331 :	± 500	262	2 ±	: 36	3	329		± 472	1600	±	2466
30	73	± 156	75	5 ±	: 18	0	192	:	± 298	850	±	1599
40	107	± 179	67	7 ±	: 16	1	164		± 224	726	±	1256
50	68 :	± 125	35	5 ±	. 8	0	964			656	±	1255
60	9 :	± 22	94	ŧ ±	22	7	52	:	± 123	685	±	1259
Total	1604 :	± 1068	1455	5 ±	124	6	2592	:	± 2969	5740		9110
Vertical counts												
Minutes after administration							ŀ			Ī		
10	30 :	± 9	42	2 ±	: 2	6	27	=	± 15	38	±	36
20	9 :	± 12	, s) ±	: 1	2	11		± 13	98		215
30	5 :	± 12	2	2 ±		5	7	:	± 11		±	18
40	3 :	± 5		2 ±	:	4	6				±	4
50	2 :	± 3	1	l ±	:	2	4		± 6	1	±	2
60		± 0	ł.	2 ±		6	2		± 4	0		0
Total	48	± 31	58	- } ±		3	57		± 53	149		265

Each value shows mean \pm S.D.

Table 25-1 Urinary examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole				
mg/kg	0	62.5	250	1000		
Number of males	6	6	6	6		
Volume (mL): Mean ± S.D.	17.0 ± 4.8	23.3 ± 7.5	17.2 ± 4.4	14.6 ± 3.7		
Specific gravity: Mean ± S.D.	1.044 ± 0.005	1.032 ± 0.010	1.047 ± 0.008	1.054 ± 0.014		
Color						
Light yellow	6	6	6	6		
pН						
8.5	6	6	3	6		
9.0	0	0	3	0		
Protein						
10∼20 mg/dL	1	1	0	0		
30 mg/dL	4	4	4	2		
100 mg/dL	1	1	2	4		
Glucose						
Negative	6	6	6	6		
Ketone body						
Negative	6	5	5	4		
Slight	0	1	1	2		
Bilirubin			1			
Negative	6	6	6	6		
Occult blood						
Negative	4	5	5	3		
Trace	2	1	0	3		
Slight	0	0	1	0		
Urobilinogen						
Normal	6	6	6	5		
1 mg/dL	0	0	0	1		

Table 25-2 Urinary examination of male rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole					
mg/kg	0	62.5	250	1000			
Number of males	6	6	6	6			
Urinary sediments							
Epithelial cells							
$0\sim20$ cells/100 fields	6	6	6	6			
Erythrocytes				-			
$0\sim20$ cells/100 fields	6	6	6	6			
Leukocytes				_			
$0\sim20$ cells/100 fields	6	6	6	6			
Casts				_			
Not observed	6	6	6	6			
Crystals				_			
Not observed	4	3	4	3			
Observed	2	3	2	3			

Table 26-1 Urinary examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole			
mg/kg	0	62.5	250	1000	
Number of females	6	6	6	6	
Volume (mL): Mean ± S.D.	29.9 ± 3.8	24.2 ± 3.9	28.2 ± 6.8	35.9 ± 9.9	
Specific gravity: Mean ± S.D.	1.032 ± 0.005	1.036 ± 0.005	1.033 ± 0.005	1.027 ± 0.005	
Color				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Light yellow	6	6	6	6	
pH					
5.5	0	2	1	0	
6.0	1	0	0	0	
6.5	3	2	0	3	
7.0	0	0	3	1	
7.5	1	2	0	2	
8.0	1	0	1	0	
8.5	0	0	1	0	
Protein			,		
Negative	2	3	5	6	
10∼20 mg/dL	4	1	0	0	
30 mg/dL	0	1	1	0	
100 mg/dL	0	1	0	0	
Glucose					
Negative	6	6	6	6	
Ketone body					
Negative	6	6	5	6	
Slight	0	0	1	0	
Bilirubin	1				
Negative	6	6	6	6	
Occult blood					
Negative	6	6	6	6	
Urobilinogen					
Normal	6	5	5	6	
1 mg/dL	0	1	1	n	

Table 26-2 Urinary examination of female rats on termination of administration period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole					
mg/kg	0	62.5	250	1000			
Number of females	6	6	6	6			
Urinary sediments							
Epithelial cells	1						
$0\sim$ 20 cells/100 fields	6	6	6	6			
Erythrocytes							
0∼20 cells/100 fields	6	6	6	6			
Leukocytes							
$0\sim$ 20 cells/100 fields	6	6	6	6			
Casts							
Not observed	6	6	6	6			
Crystals							
Not observed	1	3	2	1			
Observed	5	3	4	5			

Table 27-1 Urinary examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole				
mg/kg	0	62.5	250	1000		
Number of males	6	6	6	6		
Volume (mL): Mean ± S.D.	20.0 ± 9.2	19.8 ± 6.5	15.2 ± 5.4	12.7 ± 2.2		
Specific gravity: Mean ± S.D.	1.043 ± 0.020	1.042 ± 0.011	1.052 ± 0.015	1.056 ± 0.008		
Color						
Light yellow	6	6	6	6		
pH						
7.5	0	0	1	0		
8.0	0	0	1	0		
8.5	6	6	3	6		
9.0	0	0	1 1	0		
Protein						
10∼20 mg/dL	0	1	0	0		
30 mg/dL	3	2	4	1		
100 mg/dL	3	3	2	5		
Glucose						
Negative	6	6	6	6		
Ketone body						
Negative	6	6	6	4		
Slight	0	0	0	2		
Bilirubin	i					
Negative	6	6	6	6		
Occult blood						
Negative	5	5	6	6		
Trace	1	1	0	0		
Urobilinogen						
Normal	6	6	6	6		

Table 27-2 Urinary examination of male rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole					
mg/kg	0	62.5	250	1000			
Number of males	6	6	6	6			
Urinary sediments							
Epithelial cells	ļ						
$0\sim$ 20 cells/100 fields	6	6	6	6			
Erythrocytes							
$0\sim$ 20 cells/100 fields	6	6	6	6			
Leukocytes							
$0\sim$ 20 cells/100 fields	6	6	6	6			
Casts			ļ				
Not observed	6	6	6	6			
Crystals		i					
Not observed	4	4	4	3			
Observed	2	2	2	3			

Table 28-1 Urinary examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetrizole				
mg/kg	0	250	1000			
Number of females	6	6	6			
Volume (mL): Mean ± S.D.	12.4 ± 4.1	13.3 ± 3.1	10.0 ± 3.4			
Specific gravity: Mean ± S.D.	1.050 ± 0.013	1.046 ± 0.005	1.058 ± 0.009			
Color						
Light yellow	6	6	6			
pH						
7.0	0	0	1			
8.5	5	4	2			
9.0	1	2	3			
Protein						
Negative	3	3	3			
10∼20 mg/dL	2	2	3			
30 mg/dL	1	1	0			
Glucose						
Negative	6	6	6			
Ketone body						
Negative	6	6	6			
Bilirubin						
Negative	6	6	6			
Occult blood						
Negative	5	5	6			
Trace	1	1	0			
Urobilinogen		-	<u>-</u>			
Normal	6	6	6			

Table 28-2 Urinary examination of female rats on termination of recovery period in combined repeat dose and reproductive/developmental toxicity screening test of bumetrizole by oral administration

Group	Control	bumetr	izole
mg/kg	0	250	1000
Number of females	6	6	6
Urinary sediments			
Epithelial cells			
$0\sim$ 20 cells/100 fields	6	6	6
Erythrocytes			
$0\sim$ 20 cells/100 fields	6	6	6
Leukocytes			
$0\sim$ 20 cells/100 fields	6	6	6
Casts			
Not observed	6	6	6
Crystals			
Not observed	2	3	3
Observed	4	3	3